BSE Live
Dec 19, 16:01Prev. Close
1279.60
Open Price
1272.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 19, 15:55Prev. Close
1280.00
Open Price
1277.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1278.20 (345)
| Key Financial Ratios of Dr Reddys Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 98.60 | 113.67 | 74.54 | 53.83 | 52.82 | |
| Diluted EPS (Rs.) | 98.18 | 113.13 | 74.17 | 53.56 | 52.51 | |
| Cash EPS (Rs.) | 127.32 | 135.92 | 92.95 | 71.55 | 67.45 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 624.06 | 548.12 | 458.39 | 396.10 | 355.80 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 624.06 | 548.12 | 458.39 | 396.10 | 355.80 | |
| Dividend / Share(Rs.) | 20.00 | 18.00 | 15.00 | 13.75 | 11.25 | |
| Revenue from Operations/Share (Rs.) | 587.50 | 571.56 | 496.70 | 397.39 | 313.50 | |
| PBDIT/Share (Rs.) | 153.40 | 171.16 | 125.29 | 95.75 | 77.13 | |
| PBIT/Share (Rs.) | 124.63 | 148.81 | 106.87 | 78.00 | 62.48 | |
| PBT/Share (Rs.) | 120.89 | 144.21 | 103.25 | 74.25 | 62.17 | |
| Net Profit/Share (Rs.) | 98.56 | 113.56 | 74.53 | 53.80 | 52.80 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 26.11 | 29.94 | 25.22 | 24.09 | 24.60 | |
| PBIT Margin (%) | 21.21 | 26.03 | 21.51 | 19.62 | 19.93 | |
| PBT Margin (%) | 20.57 | 25.23 | 20.78 | 18.68 | 19.83 | |
| Net Profit Margin (%) | 16.77 | 19.86 | 15.00 | 13.53 | 16.84 | |
| Return on Networth / Equity (%) | 15.79 | 20.71 | 16.25 | 13.58 | 14.84 | |
| Return on Capital Employed (%) | 14.25 | 18.59 | 15.98 | 12.53 | 13.41 | |
| Return on Assets (%) | 10.20 | 13.32 | 10.55 | 8.82 | 9.64 | |
| Total Debt/Equity (X) | 0.29 | 0.29 | 0.20 | 0.23 | 0.24 | |
| Asset Turnover Ratio (%) | 60.83 | 67.05 | 70.34 | 65.17 | 57.26 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 2.22 | 2.17 | 1.63 | 1.61 | 1.40 | |
| Quick Ratio (X) | 1.86 | 1.78 | 1.25 | 1.17 | 0.99 | |
| Inventory Turnover Ratio (X) | 5.81 | 6.11 | 5.53 | 5.08 | 4.99 | |
| Dividend Payout Ratio (NP) (%) | 20.29 | 15.84 | 20.13 | 25.54 | 21.31 | |
| Dividend Payout Ratio (CP) (%) | 15.70 | 13.23 | 16.14 | 19.20 | 16.68 | |
| Earnings Retention Ratio (%) | 79.71 | 84.16 | 79.87 | 74.46 | 78.69 | |
| Cash Earnings Retention Ratio (%) | 84.30 | 86.77 | 83.86 | 80.80 | 83.32 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 61,649.55 | 45,584.22 | 30,661.77 | 30,511.10 | 29,102.17 | |
| EV/Net Operating Revenue (X) | 6.16 | 4.69 | 3.64 | 4.53 | 5.49 | |
| EV/EBITDA (X) | 23.59 | 15.65 | 14.41 | 18.79 | 22.30 | |
| MarketCap/Net Operating Revenue (X) | 5.94 | 4.48 | 3.56 | 4.43 | 5.23 | |
| Retention Ratios (%) | 79.70 | 84.15 | 79.86 | 74.45 | 78.68 | |
| Price/BV (X) | 5.59 | 4.67 | 3.85 | 4.44 | 4.61 | |
| Price/Net Operating Revenue | 5.94 | 4.48 | 3.56 | 4.43 | 5.23 | |
| Earnings Yield | 0.03 | 0.04 | 0.04 | 0.03 | 0.03 |
15.12.2025
12.12.2025
25.11.2025
11.11.2025
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz